Thousands of studies across three decades. Few compounds have generated as much scientific interest as resveratrol — and few have proven as difficult to translate from the lab bench to clinical practice. This polyphenol, found in grapes, berries and red wine, activates molecular pathways linked to cellular aging, has been investigated for its association with metabolic and inflammatory biomarkers in human trials, and raises questions that science is still working to answer.
What follows is an honest summary of what the evidence says — and what it does not yet say — about what resveratrol is for, how it works inside cells, and how it fits into a cellular vitality strategy.
What is resveratrol?
Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol from the stilbene family that plants synthesize as a defensive response to pathogens, UV radiation and mechanical stress. It is found mainly in the skin of black grapes, blackberries, blueberries and red wine, though in highly variable concentrations.
It exists in two isomeric forms: trans-resveratrol (the biologically active and most studied form) and cis-resveratrol (less stable and with less documented activity). Most clinical and preclinical studies have been carried out with trans-resveratrol.
Natural sources and indicative concentrations:
| Source | Concentration (mg/100 g or mg/100 ml) |
|---|---|
| Black grape skin | 50–100 mg/100 g (highly variable) |
| Red wine | 0.1–14.3 mg/L |
| Blackberries | 0.1–0.5 mg/100 g |
| Peanuts | 0.01–0.26 mg/100 g |
| Polygonum cuspidatum extract | Up to 50% trans-resveratrol by dry weight |
The most concentrated and standardized commercial source is Polygonum cuspidatum extract (also known as Fallopia japonica or Japanese knotweed), which yields trans-resveratrol with high purity and batch-to-batch reproducibility.
Novel Food regulation in the EU: Trans-resveratrol derived from Polygonum cuspidatum is authorized as a Novel Food under Regulation (EU) 2016/1190, with a maximum authorized dose of 150 mg/day for healthy adults. This limit is relevant when interpreting studies that use higher doses.
Mechanism of action: how resveratrol works in cells
Resveratrol does not have a single point of action. It works through several molecular mechanisms that overlap and reinforce one another — which explains both the breadth of its research profile and the difficulty of isolating a specific clinical effect.
How does resveratrol activate sirtuins?
The most studied pathway is the activation of sirtuins, particularly SIRT1 and SIRT3. Sirtuins are NAD+-dependent deacetylases that regulate gene expression, DNA repair, mitochondrial function and the cellular stress response. Studies in yeast models showed that resveratrol activates SIRT1 and extends lifespan, a finding that was later replicated in animal models. Subsequent research qualified that part of this activation may be indirect, mediated by the inhibition of phosphodiesterases and the consequent rise in cAMP and activation of AMPK.
Important: These mechanisms are well documented in cell and animal models. Direct extrapolation to clinical benefits in humans requires caution and is addressed in the clinical evidence section.
For a broader look at the ingredients that act on this pathway, see the complete nicotinamide riboside (NR) profile.
Inhibition of NF-κB and inflammatory pathways
Another well-characterized pathway is the inhibition of the transcription factor NF-κB, one of the central regulators of the inflammatory response. In in vitro studies, this inhibition reduces the production of pro-inflammatory cytokines such as IL-6, TNF-α and IL-1β. Observational studies in humans have found associations between resveratrol supplementation and reductions in circulating inflammatory markers, although results are heterogeneous.
Activation of AMPK and energy metabolism
AMP-activated protein kinase (AMPK) is a cellular energy sensor that, when activated, stimulates fatty acid oxidation, mitochondrial biogenesis and autophagy. Resveratrol activates AMPK both directly and through the inhibition of phosphodiesterases. This pathway underlies the studies on resveratrol and glucose metabolism.
Direct and indirect antioxidant activity
Resveratrol can act as a direct antioxidant (donating electrons to free radicals) and as an indirect inducer of the Nrf2 pathway, which regulates the expression of endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase. The indirect antioxidant activity via Nrf2 is considered more physiologically relevant than its direct action as a radical scavenger.
Summary of molecular pathways
| Pathway | Documented effect | Level of evidence |
|---|---|---|
| SIRT1/SIRT3 activation | Epigenetic regulation, mitochondrial function | Robust preclinical; limited clinical |
| NF-κB inhibition | Reduction of inflammatory markers | Robust preclinical; heterogeneous clinical |
| AMPK activation | Improved insulin sensitivity, mitochondrial biogenesis | Robust preclinical; moderate clinical |
| Nrf2 induction | Increase in endogenous antioxidants | Moderate preclinical; scarce clinical |
| COX-1/COX-2 inhibition | Reduction of inflammatory prostaglandins | In vitro; clinical relevance not established; preclinical data only. |
What has resveratrol shown in human clinical trials?
Promising results in specific biomarkers. Clinical evidence still insufficient to establish definitive benefits for most outcomes. That is the honest synthesis — and the strongest studies cluster around glucose metabolism and inflammatory markers.
Most resveratrol research has been conducted in preclinical models. Human clinical trials are more limited in number, sample size and duration. The most relevant findings are summarized below by area.
Glucose metabolism and insulin sensitivity
A randomized clinical trial by Brasnyó et al. (2011) with 19 patients with type 2 diabetes documented that 10 mg/day of resveratrol (two 5 mg doses) over 4 weeks was associated with a reduction in insulin resistance measured by HOMA-IR. However, a later systematic review that analyzed 11 RCTs with 388 participants found heterogeneous results: the effect on blood glucose was significant only in type 2 diabetes subgroups, not in a healthy population.
Dosage note: Several of these studies used doses of 500–2000 mg/day, far above the Novel Food limit of 150 mg/day authorized in the EU. The effects observed at doses ≤150 mg/day in humans are less documented. The study by Brasnyó et al. (2011) used a dose of 10 mg/day (two 5 mg doses), well below the EU Novel Food limit (150 mg/day); the mechanisms at this dose are not fully elucidated and the study has not been independently replicated at that specific dose.
Inflammatory markers
Several meta-analyses of randomized trials have documented that resveratrol supplementation was associated with reductions in circulating inflammatory markers, in particular C-reactive protein (CRP), compared with placebo. Results for IL-6 are less consistent and between-study heterogeneity is moderate-to-high, which limits how far the conclusions can be generalized.
Cardiovascular function
A trial with 75 patients with stable coronary disease showed that supplementation with resveratrol (10 mg/day) combined with calcium fructoborate for 3 months improved endothelial function measured by flow-mediated dilation (FMD) by 1.5% relative to placebo. Because the study evaluated a combination of compounds, the effect cannot be attributed to resveratrol alone. Effects on plasma lipids (LDL cholesterol, triglycerides) have been inconsistent across studies.
Cognitive function and neuroprotection
A double-blind RCT by Witte et al. (2014) with 46 older adults (aged 50–75) documented that 200 mg/day of resveratrol over 26 weeks was associated with better verbal memory and greater functional connectivity in hippocampal regions measured by fMRI, compared with placebo. It is one of the most cited trials in the cognitive field, although the sample size is limited.
Summary table of key clinical trials
| Study | n | Dose | Duration | Primary outcome | Result | Level |
|---|---|---|---|---|---|---|
| Brasnyó et al. (2011) | 19 | 10 mg/day (2×5 mg) | 4 weeks | HOMA-IR (insulin resistance) | Significant reduction | B (RCT, small n) |
| Liu et al. (2014) | 388 (meta) | 8–3000 mg/day | Variable | Blood glucose, HOMA-IR | Effect in T2DM, not in healthy subjects | A (meta-analysis) |
| Meta-analysis of RCTs | — | Variable | Variable | CRP, IL-6 | CRP reduction; heterogeneous IL-6 | A (meta-analysis) |
| Militaru et al. (2013) | 75 | 10 mg/day | 3 months | Endothelial FMD | Improvement +1.5% (combined with calcium fructoborate) | B (RCT) |
| Witte et al. (2014) | 46 | 200 mg/day | 26 weeks | Verbal memory | Significant improvement | B (RCT) |
Cross-cutting limitation: The oral bioavailability of trans-resveratrol is very low (~1% of the ingested dose reaches systemic circulation unmetabolized), which complicates the interpretation of studies and comparisons across doses. Formulations with piperine or nanoencapsulation aim to improve this parameter.
Bioavailability: the Achilles' heel of oral resveratrol
Here lies the central problem with resveratrol as an oral supplement: it is well absorbed in the small intestine, but undergoes intense presystemic metabolism — glucuronide and sulfate conjugation in the intestinal wall and the liver — leaving only about 1% of the ingested dose circulating as free trans-resveratrol in plasma.
Why does the bioavailability of oral trans-resveratrol matter?
A compound with low oral bioavailability can show potent effects in in vitro studies (where it is applied directly to cells) without those effects being reproduced in humans at equivalent oral doses. This is one of the reasons why resveratrol's preclinical results are not always replicated in clinical trials.
Strategies to improve bioavailability:
- Piperine: Co-administration with piperine has been explored as a strategy to improve the bioavailability of polyphenols. The best-known data come from studies with curcumin, where 20 mg of piperine increased bioavailability by 2000% in rats and 154% in humans.
- Piperine and resveratrol: as for resveratrol specifically, a pharmacokinetic study in an animal model (mouse) documented that co-administration of piperine increased the plasma area under the curve of resveratrol by approximately 229%. This effect is attributed mainly to piperine's inhibition of presystemic metabolism.
- A prudent reading: since these are preclinical data, they are not directly extrapolable to humans; the 229% increase reflects the plasma area under the curve, not necessarily bioavailability in target tissues, and the clinical efficacy of this combination at authorized doses (≤150 mg/day) has not been evaluated in controlled trials.
- Nanoencapsulation and liposomes: Formulations that protect resveratrol from presystemic metabolism. The clinical evidence with these formulations is still scarce.
- Micronization: Reducing particle size improves the absorption surface area. Some studies show modest improvements in plasma Cmax.
Practical implication: Studies using doses of 500–2000 mg/day may be partly compensating for low bioavailability with quantity. At doses of 150 mg/day (EU Novel Food limit), plasma levels of free trans-resveratrol are low, and the clinical effects at this specific dose are less documented than at higher doses.
Resveratrol and cellular vitality: NAD+, sirtuins and aging
Interest in resveratrol within the field of cellular vitality centers on its relationship with the NAD+/sirtuin axis, one of the most studied molecular pathways in the biology of aging.
What is the relationship between resveratrol and NAD+?
Resveratrol does not directly raise NAD+ levels. Its mechanism is different: it activates sirtuins (especially SIRT1), which are enzymes that consume NAD+ to carry out their deacetylation functions. If you want to understand what NAD+ is and why it matters for cellular vitality, you can read our guide on what NAD+ is and how it influences your health. Resveratrol and NAD+ precursors (such as nicotinamide riboside, NR) therefore act on the same pathway but from complementary angles:
- NAD+ precursors (NR, NMN): increase the available substrate (NAD+) for sirtuins to work with.
- Resveratrol: activates sirtuins so they use that NAD+ more efficiently.
This complementarity is the rationale behind formulas that combine both types of compounds. However, it is important to note that the clinical evidence for this synergy in humans is still preliminary.
The rationale for combining NAD+ precursors (such as NR) with sirtuin activators (such as resveratrol) is based on their complementary action on the same molecular axis. Studies in animal models have shown that NR on its own improves mitochondrial function and oxidative metabolism in mice fed a high-fat diet. The specific synergy of the NR + resveratrol combination has not been evaluated in human clinical trials.
Resveratrol and cellular senescence
Cellular senescence — the state in which cells stop dividing but remain metabolically active and secrete pro-inflammatory factors — is one of the hallmarks of aging. In vitro studies show that resveratrol can delay the onset of senescence and reduce the senescence-associated secretory phenotype (SASP) in human cell lines (Bhullar & Hubbard, 2015). These data are promising, but they sit at level D evidence (in vitro); there are no human clinical trials that have directly measured the effect of resveratrol on senescent cell burden.
Resveratrol and mitochondrial function
A clinical trial with 11 obese men showed that 150 mg/day of resveratrol over 30 days improved mitochondrial function in skeletal muscle (measured by high-resolution respirometry in muscle biopsies) and reduced fasting glucose and insulin levels. This study is relevant because it used exactly the maximum dose authorized by the EU Novel Food regulation (150 mg/day), although the sample size is very small (n=11) and the participants were obese, not a generally healthy population.
To explore the mechanisms of cellular vitality and the compounds that act on this pathway in more depth, see the complete PLENIAGE® cellular vitality guide.
Resveratrol alongside quercetin and berberine: the polyphenol trio
Resveratrol is rarely studied in isolation in the context of cellular vitality. Preclinical research has explored its combination with other polyphenols that act on complementary or synergistic molecular pathways.
Quercetin (present in Sophora japonica, apple, onion) has been investigated as a potential senolytic agent (one that acts on senescent cells) in preclinical models. Some pilot studies in humans have explored combinations of quercetin with pharmacological agents in specific clinical contexts, although these designs cannot be extrapolated to supplementation with quercetin on its own. The evidence for quercetin as a senolytic in healthy humans is still very preliminary.
Berberine (present in Berberis vulgaris) is a potent AMPK activator with more solid clinical evidence than resveratrol in the context of glucose metabolism. A meta-analysis of 27 RCTs (n=2569) showed that berberine reduced HbA1c by −0.71% (95% CI: −0.99 to −0.43) in patients with type 2 diabetes. This figure comes from studies with isolated berberine at high doses in patients with diagnosed diabetes; it is not a property of the product nor extrapolable to the combined PLENIAGE® formula. Berberine also activates SIRT1 and modulates the gut microbiota.
Combining all three: The rationale for combining resveratrol + quercetin + berberine is based on their convergence on common pathways (AMPK, SIRT1, NF-κB) through distinct entry mechanisms, which could theoretically produce additive effects at lower individual doses. However, there are no published clinical trials that have specifically tested this triple combination in humans. The evidence for synergy is preclinical.
Important: Any product that combines these three ingredients cannot claim the results of the individual studies of each one. The studies were conducted with each compound separately, at specific doses, in specific populations.
Dosage, safety and contraindications
How much resveratrol can you take per day?
The maximum authorized dose for trans-resveratrol derived from Polygonum cuspidatum in the European Union is 150 mg/day (EU Novel Food Regulation 2016/1190). This is the regulatory reference dose for supplements in Spain and the EU.
Clinical studies have used a very wide range of doses (5–5000 mg/day), which makes it difficult to establish an optimal dose. The effects observed in some trials (especially the metabolic ones) have been documented at doses of 500–2000 mg/day, above the Novel Food limit. At 150 mg/day, the most relevant clinical evidence is the study by Timmers et al. (2011) in obese men (n=11).
Safety profile
Resveratrol has a favorable safety profile at low-to-moderate doses. The most frequent adverse effects reported in clinical trials at high doses (≥1000 mg/day) are gastrointestinal: nausea, diarrhea and abdominal discomfort. At doses ≤150 mg/day, studies have not reported significant adverse effects.
Contraindications and precautions
- Anticoagulants (warfarin, acenocoumarol): Resveratrol may inhibit CYP2C9, the enzyme that metabolizes warfarin, with the potential to increase its anticoagulant effect. Caution and monitoring are recommended in anticoagulated patients.
- Pregnancy and breastfeeding: There are no safety data in pregnant women. Its use is not advised as a precaution.
- Hormone-dependent tumors: Resveratrol has shown weak estrogenic activity in laboratory studies (in vitro). There is no clinical evidence of risk in humans, but as a precaution it is recommended to consult a doctor before using resveratrol in people with a history of hormone-dependent tumors.
- Surgery: Because of its potential antiplatelet effect, discontinuation 2 weeks before surgical procedures is recommended.
- Interactions with drugs metabolized by CYP3A4: Resveratrol may inhibit this enzyme at high doses, affecting the metabolism of some medications.
This information is for educational purposes. Always consult your doctor or pharmacist before starting any supplementation, especially if you take medication or have pre-existing health conditions.
How to take resveratrol: timing, format and combinations
When and how should resveratrol be taken?
There is no established clinical consensus on the optimal timing. Practical recommendations are based on the compound's pharmacokinetics:
- With food: The presence of fats in the digestive tract may slightly improve the absorption of resveratrol, which is lipophilic. Taking it with the main meal is the most widely shared recommendation.
- Splitting the dose: Given the rapid metabolism of free trans-resveratrol (plasma half-life of approximately 1–3 hours; Walle, 2011), some researchers suggest dividing the daily dose into two intakes to keep plasma levels more stable. However, resveratrol metabolites have longer half-lives and may retain some biological activity. The clinical evidence comparing a single dose with a split dose is limited.
- Format: Capsules with standardized Polygonum cuspidatum extract are the most widely used format in clinical trials and allow the trans-resveratrol dose to be controlled precisely.
Studied combinations:
- With piperine: Co-administration with piperine may increase the plasma area under the curve of resveratrol, according to a pharmacokinetic study in an animal model (mouse). Since these are preclinical data, they are not directly extrapolable to humans, and the effects of this combination at authorized doses (≤150 mg/day of resveratrol) have not been evaluated in controlled trials.
- With NR (nicotinamide riboside): A rational combination on the NAD+/sirtuin axis. No specific human clinical trials validate the synergy.
- With quercetin and berberine: A combination of polyphenols with complementary pathways. No clinical trials of the triple combination.
PLENIAGE® Pro NAD+ NR Advanced Edition incorporates resveratrol 147 mg (derived from Polygonum cuspidatum) alongside NR 50 mg, quercetin 71.25 mg (from Sophora japonica), berberine 72.75 mg (from Berberis vulgaris) and piperine 2.375 mg as a bioenhancer. Each ingredient has been investigated individually; the specific combination of this formula has not been the subject of its own clinical trial. The resveratrol dose (147 mg) is within the EU Novel Food limit of 150 mg/day.
Resveratrol: what science has not yet resolved
The research on resveratrol is extensive — and, honestly, also frustrating. Well-characterized molecular mechanisms, promising clinical signals, and yet a persistent gap between what happens in the lab and what can be stated with certainty in healthy humans. These are the limitations that any informed consumer should be aware of.
- Small sample size: Most human RCTs have fewer than 100 participants, which limits statistical power and the generalizability of results.
- Dose heterogeneity: Studies use doses ranging from 5 mg to 5000 mg/day, making it difficult to compare results and establish a dose-response curve.
- Low oral bioavailability: Only ~1% of the oral dose circulates as free trans-resveratrol. This raises doubts about whether the observed effects are due to resveratrol or to its metabolites (resveratrol-3-sulfate, resveratrol-3-glucuronide), which may have biological activity of their own.
- Short study duration: Most trials last between 4 weeks and 6 months. Long-term effects (over years) on clinically relevant outcomes (cardiovascular events, diabetes incidence, cognitive decline) have not been evaluated.
- Specific populations: Many studies are conducted in populations with disease (type 2 diabetes, obesity, cardiovascular disease). Effects in healthy adults are less documented.
- Absence of EFSA claims: The European Food Safety Authority (EFSA) has not authorized any health claim for resveratrol as such. The claims authorized on products containing resveratrol come from other ingredients in the formula (such as niacin, if NR is present as a source of niacin).
None of these limitations invalidates the scientific interest of the compound. What they do is pinpoint exactly where we stand: facing an ingredient with solid molecular mechanisms and clinical signals pointing in the right direction, but one that needs more research in healthy humans before definitive benefits can be established.
Frequently asked questions about resveratrol
Is resveratrol useful for weight loss?
The current evidence does not support the use of resveratrol as a weight-loss agent in humans. Some studies in obese mice showed a reduction in body weight, but these results have not been consistently replicated in human clinical trials. Systematic reviews of the available clinical trials have not found a significant effect of resveratrol on body weight in humans. Some clinical trials have observed improvements in metabolic markers (such as blood glucose or HOMA-IR) in people with type 2 diabetes, but this is different from producing weight loss.
Is the resveratrol in red wine enough?
No. Red wine contains between 0.1 and 14.3 mg of resveratrol per liter, with an average of approximately 2–4 mg/L. To reach the 150 mg/day set by the EU Novel Food limit you would have to drink between 10 and 75 liters of wine a day, which is obviously unfeasible and counterproductive because of the alcohol. Supplements with standardized Polygonum cuspidatum extract are the only practical way to reach relevant doses.
Does resveratrol have proven anti-aging effects in humans?
There are no clinical trials that have demonstrated anti-aging effects in the sense of extending lifespan or reversing aging in humans. Studies in model organisms (yeast, worms, flies, mice) showed lifespan extension, but these results have not been replicated in primates or humans. What does exist are studies showing improvements in biomarkers associated with aging (mitochondrial function, inflammatory markers, insulin sensitivity) in specific populations.
Can resveratrol be taken daily?
The longest clinical studies have evaluated daily supplementation for up to 12 months without reporting significant adverse effects at doses ≤150 mg/day. The long-term safety profile (more than 1 year) has not been evaluated in controlled clinical trials. As with any supplement, it is recommended to consult a health professional, especially if you take medication or have pre-existing health conditions.
Does resveratrol interact with medications?
Yes, potentially. The best-documented interactions are with anticoagulants (warfarin, acenocoumarol) through inhibition of CYP2C9, and with other drugs metabolized by CYP3A4 at high doses. If you take medication, consult your doctor or pharmacist before starting supplementation.
Resveratrol is one of the most researched polyphenols in the field of cellular vitality. Its ability to activate sirtuins, modulate inflammatory pathways and act on mitochondrial function is well documented in preclinical models. In humans, the most consistent evidence documents changes in metabolic markers in people with type 2 diabetes and reductions in circulating inflammatory markers.
The real limitations of the evidence — low oral bioavailability, studies with small samples, highly variable doses and the absence of long-term trials in a healthy population — do not invalidate the scientific interest of the compound, but they do call for honest communication about what is known and what remains to be demonstrated.
If you are interested in exploring how resveratrol fits into a cellular vitality strategy alongside other compounds with complementary mechanisms, you can read our complete cellular vitality guide or browse the PLENIAGE® cellular vitality supplements collection.
References
The statements in this article are based on the available scientific literature. The references for the studies cited in this article are listed below.
- Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191-6. PMID: 12939617.
- Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-42. PMID: 17086191.
- Brasnyó P, Molnár GA, Mohás M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106(3):383-9. PMID: 21385509.
- Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215:9-15. PMID: 21261636.
- Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612-22. PMID: 22055504.
- Johnson JJ, Nihal M, Siddiqui IA, et al. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res. 2011;55(8):1169-76. PMID: 21714124.
- Militaru C, Donoiu I, Craciun A, et al. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition. 2013;29(1):178-83. PMID: 23153742.
- Liu K, Zhou R, Wang B, Mi MT. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2014;99(6):1510-9. PMID: 24695890.
- Witte AV, Kerti L, Margulies DS, Flöel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci. 2014;34(23):7862-70. PMID: 24899709.
- Bhullar KS, Hubbard BP. Lifespan and healthspan extension by resveratrol. Biochim Biophys Acta. 2015;1852(6):1209-18. PMID: 25640851.
- Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. PMID: 27721479.